These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 23549785)
1. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. Radtke S; Milanovic M; Rossé C; De Rycker M; Lachmann S; Hibbert A; Kermorgant S; Parker PJ J Cell Sci; 2013 Jun; 126(Pt 11):2381-91. PubMed ID: 23549785 [TBL] [Abstract][Full Text] [Related]
2. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2. Hu CT; Cheng CC; Pan SM; Wu JR; Wu WS Cell Signal; 2013 Jun; 25(6):1457-67. PubMed ID: 23524339 [TBL] [Abstract][Full Text] [Related]
3. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Ma PC; Tretiakova MS; Nallasura V; Jagadeeswaran R; Husain AN; Salgia R Br J Cancer; 2007 Aug; 97(3):368-77. PubMed ID: 17667909 [TBL] [Abstract][Full Text] [Related]
4. GIT1 is a novel MEK1-ERK1/2 scaffold that localizes to focal adhesions. Zhang N; Cai W; Yin G; Nagel DJ; Berk BC Cell Biol Int; 2009 Dec; 34(1):41-7. PubMed ID: 19947948 [TBL] [Abstract][Full Text] [Related]
5. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells. Otabe O; Kikuchi K; Tsuchiya K; Katsumi Y; Yagyu S; Miyachi M; Iehara T; Hosoi H Oncol Rep; 2017 Jan; 37(1):98-104. PubMed ID: 27840956 [TBL] [Abstract][Full Text] [Related]
6. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Tjin EP; Groen RW; Vogelzang I; Derksen PW; Klok MD; Meijer HP; van Eeden S; Pals ST; Spaargaren M Blood; 2006 Jan; 107(2):760-8. PubMed ID: 16189274 [TBL] [Abstract][Full Text] [Related]
7. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Jagadeeswaran R; Jagadeeswaran S; Bindokas VP; Salgia R Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1488-94. PubMed ID: 17322284 [TBL] [Abstract][Full Text] [Related]
8. PKCε-mediated c-Met endosomal processing directs fluctuant c-Met-JNK-paxillin signaling for tumor progression of HepG2. Hu CT; Cheng CC; Wu JR; Pan SM; Wu WS Cell Signal; 2015 Jul; 27(7):1544-55. PubMed ID: 25778903 [TBL] [Abstract][Full Text] [Related]
9. Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines. Gusenbauer S; Zanucco E; Knyazev P; Ullrich A Mol Cancer; 2015 Mar; 14():54. PubMed ID: 25884419 [TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association. Liu ZX; Yu CF; Nickel C; Thomas S; Cantley LG J Biol Chem; 2002 Mar; 277(12):10452-8. PubMed ID: 11784715 [TBL] [Abstract][Full Text] [Related]
11. Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. Tanimura S; Nomura K; Ozaki K; Tsujimoto M; Kondo T; Kohno M J Biol Chem; 2002 Aug; 277(31):28256-64. PubMed ID: 12032150 [TBL] [Abstract][Full Text] [Related]
12. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685 [TBL] [Abstract][Full Text] [Related]
14. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991 [TBL] [Abstract][Full Text] [Related]
16. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118 [TBL] [Abstract][Full Text] [Related]
17. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813 [TBL] [Abstract][Full Text] [Related]
18. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. You B; Yang YL; Xu Z; Dai Y; Liu S; Mao JH; Tetsu O; Li H; Jablons DM; You L Oncotarget; 2015 Feb; 6(6):4357-68. PubMed ID: 25738359 [TBL] [Abstract][Full Text] [Related]
20. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility. Fang JD; Lee SL Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]